![](/img/cover-not-exists.png)
Brigatinib versus crizotinib in patients with ALK inhibitorânaive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial
Califano, R., Camidge, D., Kim, H.-R., Ahn, M.-J., Yang, J., Han, J.-Y., Hochmair, M., Lee, K.H., Delmonte, A., Campelo, M.R. Garcia, Kim, D.-W., Griesinger, F., Felip, E., Spira, A., Gettinger, S., TVolume:
139
Journal:
Lung Cancer
DOI:
10.1016/S0169-5002(20)30164-1
Date:
January, 2020
File:
PDF, 56 KB
2020